
Autobahn Therapeutics: A regenerative medicine company revitalizing health for CNS disorder patients.
Autobahn Therapeutics was founded with the mission to improve the health and quality of life for individuals affected by central nervous system (CNS) disorders. The company focuses on harnessing the regenerative power of the human body to develop next-generation therapies aimed at restoring brain health. Autobahn Therapeutics targets both rare and prevalent CNS diseases, striving to create innovative regenerative medicines that can significantly impact patient outcomes.
Notable affiliated individuals and investors include leading experts in regenerative medicine and prominent venture capital firms specializing in biotech. Autobahn Therapeutics has achieved key milestones in advancing its therapeutic pipeline, demonstrating promising preclinical results. The company's work has the potential to transform treatment paradigms for CNS disorders, offering new hope to patients and contributing to the broader field of regenerative medicine.

Pipeline Therapeutics

Abata Therapeutics
abatatx.com

Juventas Therapeutics
juventasinc.com

Bolden Therapeutics

Novoron Bioscience
novoron.com

Axial Therapeutics

Caeregen Therapeutics
caeregen.com

Cell Reprogramming & Therapeutics

CuraSen Therapeutics
curasen.com

ReNetX Bio
renetx.com

APstem Therapeutics
apstemtx.com

Regennova
regennova.com

Camino Pharma
caminopharma.com

Myrobalan Therapeutics
myrotx.com

Endogena Therapeutics
Companies similar to Autobahn Therapeutics include Pipeline Therapeutics, Abata Therapeutics, Juventas Therapeutics and Bolden Therapeutics.
Autobahn Therapeutics was founded in 2017.
Autobahn Therapeutics' headquarters is located in San Diego, CA, US.
Autobahn Therapeutics' most recent funding round was for $32.7M (USD) in September 2022.
As of Sep 8, 2022, Autobahn Therapeutics has raised a total of $108.7M (USD).
Autobahn Therapeutics has 25 employees as of Feb 4, 2024.